Physician profile
Daryl K Boffard
NPI 1497763874
$55,223.99
in general payments reported to CMS, 2019-2025
31 companies · $3,659 in 2025
The $3,659 reported for 2025 was more than what 92% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $1,748 · 2021: $16K · 2022: $15K · 2023: $5,071 · 2024: $650 · 2025: $3,659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,243 · Food and Beverage: $1,945 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,242.77 |
| Food and Beverage | $1,944.78 |
| Education | $192.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $31,433.16 | 2021-2025 | Nexplanon |
| Duchesnay USA Incorporated | $6,268.50 | 2019 | |
| Coopersurgical, INC. | $4,905.46 | 2019-2024 | Summit Doppler |
| Merck Sharp & Dohme LLC | $4,899.31 | 2019-2021 | |
| Exeltis, USA INC. | $1,691.04 | 2019-2025 | Tyblume, Slynd, Solosec |
| Myovant Sciences INC. | $1,631.67 | 2021-2022 | |
| Ethicon INC. | $1,450.57 | 2019 | |
| Mayne Pharma Commercial LLC | $435.00 | 2021-2025 | |
| Avion Pharmaceuticals | $356.63 | 2019-2022 | |
| Astellas Pharma US INC | $340.63 | 2023-2025 | Veozah |
| Abbvie INC. | $268.12 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Therapeuticsmd, INC. | $223.71 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $201.35 | 2023-2025 | Myfembree |
| Millicent US INC | $165.44 | 2021-2025 | Femring, Intrarosa, Femlyv |
| Scynexis, INC. | $161.35 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gynesonics, INC. | $147.88 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Hologic Sales and Service, LLC | $108.11 | 2021-2024 | Aptima |
| Novo Nordisk INC | $107.64 | 2025 | Wegovy |
| Dysis Medical, INC. | $76.15 | 2020-2022 | |
| Evofem Biosciences, INC. | $70.04 | 2021-2024 | |
| Vertical Pharmaceuticals, LLC | $54.59 | 2019 | |
| Allergan, INC. | $51.58 | 2019-2020 | |
| Agile Therapeutics, INC. | $43.08 | 2022 | |
| Lupin INC. | $39.47 | 2019-2021 | |
| Meditrina | $33.97 | 2023-2025 | |
| Aspira Women'S Health INC | $16.76 | 2019 | |
| Amag Pharmaceuticals, INC. | $16.64 | 2019 | |
| Pfizer INC. | $13.96 | 2022 | |
| Gilead Sciences, INC. | $11.17 | 2019 | |
| Alydia Health | $1.01 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daryl Boffard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.